Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates

Core Insights - Catalent (CTLT) reported a quarterly loss of $0.13 per share, missing the Zacks Consensus Estimate of $0.11, and compared to a loss of $0.10 per share a year ago, representing an earnings surprise of -218.18% [1] - The company posted revenues of $1.02 billion for the quarter ended September 2024, missing the Zacks Consensus Estimate by 5.28%, but showing an increase from year-ago revenues of $982 million [2] - Catalent shares have increased approximately 30.6% since the beginning of the year, outperforming the S&P 500's gain of 19.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.23 on revenues of $1.14 billion, and for the current fiscal year, it is $1.28 on revenues of $4.74 billion [7] - The estimate revisions trend for Catalent is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Catalent belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Another company in the same industry, OptiNose (OPTN), is expected to report a quarterly loss of $0.05 per share, reflecting a year-over-year change of +37.5%, with revenues projected at $22.84 million, up 15.2% from the previous year [9]